<p>Nebula Research &amp; Development LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免費報告) 的股份增加了 82.4%。該基金在此期間購買了額外的 31,570 股後，持有該公司 69,884 股股票。Nebula Research &amp; Development LLC 在最近一個季度末持有 Kiniksa Pharmaceuticals International 0.09% 的股份，價值 1,934,000 美元。</p>
<p>其他一些機構投資者最近也對該股票的持倉進行了調整。Nuveen LLC 在第一季度獲得了 Kiniksa Pharmaceuticals International 的新股份，價值約為 16,992,000 美元。Arrowstreet Capital Limited Partnership 在第二季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值約為 20,349,000 美元。Qube Research &amp; Technologies Ltd 在第二季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 277.8%。Qube Research &amp; Technologies Ltd 現在持有 888,364 股該公司的股票，價值 24,581,000 美元，此前在此期間又購買了 653,236 股。Acadian Asset Management LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 170.3%。Acadian Asset Management LLC 現在持有 1,034,321 股該公司的股票，價值 22,961,000 美元，此前在上個季度又購買了 651,700 股。最後，AQR Capital Management LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 149.1%。AQR Capital Management LLC 現在持有 491,761 股該公司的股票，價值 10,922,000 美元，此前在上個季度又購買了 294,319 股。機構投資者持有該公司 53.95% 的股票。</p>
<h2>Kiniksa Pharmaceuticals International 的內部交易</h2>
<p>在相關消息中，首席財務官 Mark Ragosa 於 12 月 8 日星期一出售了 42,841 股 Kiniksa Pharmaceuticals International 的股票。股票以平均價格 41.49 美元出售，總價值為 1,777,473.09 美元。出售完成後，首席財務官持有 31,086 股該公司的股票，價值約為 1,289,758.14 美元。這筆交易代表其持倉減少了 57.95%。該交易在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席運營官 Eben Tessari 於 11 月 17 日星期一出售了 12,470 股該公司的股票。股票以平均價格 41.24 美元出售，總交易額為 514,262.80 美元。出售後，首席運營官持有 22,714 股該公司的股票，價值 936,725.36 美元。這筆交易代表其持倉減少了 35.44%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 537,280 股公司股票，價值 20,844,046 美元。公司內部人士持有該公司 53.48% 的股票。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些研究公司最近對 KNSA 發表了評論。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Kiniksa Pharmaceuticals International 股票的 &#34;持有 (c)&#34; 評級。Wells Fargo &amp; Company 將 Kiniksa Pharmaceuticals International 股票的目標價從 42.00 美元上調至 45.00 美元，並在 9 月 25 日星期四的研究報告中給予該公司 &#34;超配&#34; 評級。Zacks Research 在 10 月 6 日星期一的報告中將 Kiniksa Pharmaceuticals International 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。Wedbush 在 12 月 2 日星期二的研究報告中重新發布了 &#34;跑贏大盤&#34; 評級，並對 Kiniksa Pharmaceuticals International 的股票設定了 48.00 美元的價格目標。最後，高盛集團在 10 月 29 日星期三的研究報告中將 Kiniksa Pharmaceuticals International 的目標價從 45.00 美元上調至 55.00 美元，並給予該公司 &#34;買入&#34; 評級。六位研究分析師對該股票給予了買入評級，兩位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 52.00 美元。</p>
<p><strong>查看我們關於 Kiniksa Pharmaceuticals International 的最新研究報告</strong></p>
<h2>Kiniksa Pharmaceuticals International 股票上漲 1.2%</h2>
<p>KNSA 週五開盤價為 41.01 美元。該公司的 50 日移動平均價格為 39.78 美元，200 日移動平均價格為 34.33 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低價為 17.82 美元，1 年最高價為 42.98 美元。該公司的市值為 31.1 億美元，市盈率為 91.14，貝塔值為 0.02。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近於 10 月 28 日星期二發佈了其財報。該公司報告本季度每股收益為 0.23 美元，低於共識預期的 0.31 美元，差距為 0.08 美元。Kiniksa Pharmaceuticals International 的淨利潤率為 6.01%，股本回報率為 7.46%。該公司本季度的收入為 1.8086 億美元，而分析師預期為 1.6664 億美元。在去年同期，該公司的每股收益為 -0.18 美元。該公司的季度收入同比增長 61.2%。研究分析師平均預測 Kiniksa Pharmaceuticals International, plc 本財年將發佈 -0.55 美元的每股收益。</p>
<h2>Kiniksa Pharmaceuticals International 簡介</h2>
<p>(免費報告)</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，旨在為全球面臨重大未滿足醫療需求的虛弱疾病患者提供幫助。其產品候選藥物包括 ARCALYST，一種針對複發性心包炎的白介素-1α和白介素-1β，複發性心包炎是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，目前正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 T 細胞共刺激信號，對於 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應至關重要。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>2026 年應避免的 3 只最近被下調評級的股票</li>
<li>恒生指數是什麼？</li>
<li>芯片熱潮迴歸：3 只有望大幅上漲的股票</li>
<li>3 只引領迷因股票復興的股票</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Kiniksa Pharmaceuticals International 嗎？</h2>
<p>在考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
<p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KNSA

<p>Nebula Research & Development LLC 在第二季度將其在 Kiniksa Pharmaceuticals 的股份增加了 82.4%，持有 69,884 股，價值 193 萬美元。其他機構投資者也調整了他們的持倉。內部交易包括首席財務官 Mark Ragosa 和首席運營官 Eben Tessari 的大量股票出售。分析師的評級意見不一，普遍目標價為 52.00 美元。Kiniksa 的股票目前交易價格為 41.01 美元，市值為 31.1 億美元</p>

<p>Nebula Research &amp; Development LLC raised its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 82.4% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 69,884 shares of the company's stock after purchasing an additional 31,570 shares during the period. Nebula Research &amp; Development LLC owned 0.09% of Kiniksa Pharmaceuticals International worth $1,934,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Nebula Research &amp; Development LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 免費報告) 的股份增加了 82.4%。該基金在此期間購買了額外的 31,570 股後，持有該公司 69,884 股股票。Nebula Research &amp; Development LLC 在最近一個季度末持有 Kiniksa Pharmaceuticals International 0.09% 的股份，價值 1,934,000 美元。</p>
</div><p>A number of other institutional investors have also recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $16,992,000. Arrowstreet Capital Limited Partnership bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $20,349,000. Qube Research &amp; Technologies Ltd increased its position in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period. Acadian Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after purchasing an additional 294,319 shares during the last quarter. Institutional investors own 53.95% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也對該股票的持倉進行了調整。Nuveen LLC 在第一季度獲得了 Kiniksa Pharmaceuticals International 的新股份，價值約為 16,992,000 美元。Arrowstreet Capital Limited Partnership 在第二季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值約為 20,349,000 美元。Qube Research &amp; Technologies Ltd 在第二季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 277.8%。Qube Research &amp; Technologies Ltd 現在持有 888,364 股該公司的股票，價值 24,581,000 美元，此前在此期間又購買了 653,236 股。Acadian Asset Management LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 170.3%。Acadian Asset Management LLC 現在持有 1,034,321 股該公司的股票，價值 22,961,000 美元，此前在上個季度又購買了 651,700 股。最後，AQR Capital Management LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的持倉增加了 149.1%。AQR Capital Management LLC 現在持有 491,761 股該公司的股票，價值 10,922,000 美元，此前在上個季度又購買了 294,319 股。機構投資者持有該公司 53.95% 的股票。</p>
</div><h2>Insider Transactions at Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的內部交易</h2>
</div><p>In related news, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the completion of the sale, the chief financial officer owned 31,086 shares of the company's stock, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,470 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.24, for a total transaction of $514,262.80. Following the sale, the chief operating officer owned 22,714 shares of the company's stock, valued at $936,725.36. This trade represents a 35.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 537,280 shares of company stock valued at $20,844,046. Company insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Mark Ragosa 於 12 月 8 日星期一出售了 42,841 股 Kiniksa Pharmaceuticals International 的股票。股票以平均價格 41.49 美元出售，總價值為 1,777,473.09 美元。出售完成後，首席財務官持有 31,086 股該公司的股票，價值約為 1,289,758.14 美元。這筆交易代表其持倉減少了 57.95%。該交易在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，首席運營官 Eben Tessari 於 11 月 17 日星期一出售了 12,470 股該公司的股票。股票以平均價格 41.24 美元出售，總交易額為 514,262.80 美元。出售後，首席運營官持有 22,714 股該公司的股票，價值 936,725.36 美元。這筆交易代表其持倉減少了 35.44%。該出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士已出售 537,280 股公司股票，價值 20,844,046 美元。公司內部人士持有該公司 53.48% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of research firms have recently commented on KNSA. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wells Fargo &amp; Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, September 25th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Wedbush reissued an &#34;outperform&#34; rating and issued a $48.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $52.00.</p>
<div class="lb-trans"><p>一些研究公司最近對 KNSA 發表了評論。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Kiniksa Pharmaceuticals International 股票的 &#34;持有 (c)&#34; 評級。Wells Fargo &amp; Company 將 Kiniksa Pharmaceuticals International 股票的目標價從 42.00 美元上調至 45.00 美元，並在 9 月 25 日星期四的研究報告中給予該公司 &#34;超配&#34; 評級。Zacks Research 在 10 月 6 日星期一的報告中將 Kiniksa Pharmaceuticals International 的評級從 &#34;強力買入&#34; 下調至 &#34;持有&#34;。Wedbush 在 12 月 2 日星期二的研究報告中重新發布了 &#34;跑贏大盤&#34; 評級，並對 Kiniksa Pharmaceuticals International 的股票設定了 48.00 美元的價格目標。最後，高盛集團在 10 月 29 日星期三的研究報告中將 Kiniksa Pharmaceuticals International 的目標價從 45.00 美元上調至 55.00 美元，並給予該公司 &#34;買入&#34; 評級。六位研究分析師對該股票給予了買入評級，兩位分析師對該公司給予了持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 52.00 美元。</p>
</div><p><strong>View Our Latest Research Report on Kiniksa Pharmaceuticals International</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Kiniksa Pharmaceuticals International 的最新研究報告</strong></p>
</div><h2>Kiniksa Pharmaceuticals International Trading Up 1.2%</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票上漲 1.2%</h2>
</div><p>KNSA opened at $41.01 on Friday. The company has a fifty day moving average price of $39.78 and a two-hundred day moving average price of $34.33. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98. The company has a market cap of $3.11 billion, a P/E ratio of 91.14 and a beta of 0.02.</p>
<div class="lb-trans"><p>KNSA 週五開盤價為 41.01 美元。該公司的 50 日移動平均價格為 39.78 美元，200 日移動平均價格為 34.33 美元。Kiniksa Pharmaceuticals International, plc 的 1 年最低價為 17.82 美元，1 年最高價為 42.98 美元。該公司的市值為 31.1 億美元，市盈率為 91.14，貝塔值為 0.02。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The business's quarterly revenue was up 61.2% on a year-over-year basis. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近於 10 月 28 日星期二發佈了其財報。該公司報告本季度每股收益為 0.23 美元，低於共識預期的 0.31 美元，差距為 0.08 美元。Kiniksa Pharmaceuticals International 的淨利潤率為 6.01%，股本回報率為 7.46%。該公司本季度的收入為 1.8086 億美元，而分析師預期為 1.6664 億美元。在去年同期，該公司的每股收益為 -0.18 美元。該公司的季度收入同比增長 61.2%。研究分析師平均預測 Kiniksa Pharmaceuticals International, plc 本財年將發佈 -0.55 美元的每股收益。</p>
</div><h2>Kiniksa Pharmaceuticals International Profile</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，旨在為全球面臨重大未滿足醫療需求的虛弱疾病患者提供幫助。其產品候選藥物包括 ARCALYST，一種針對複發性心包炎的白介素-1α和白介素-1β，複發性心包炎是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，目前正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 T 細胞共刺激信號，對於 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應至關重要。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>What is the Hang Seng index?</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>2026 年應避免的 3 只最近被下調評級的股票</li>
<li>恒生指數是什麼？</li>
<li>芯片熱潮迴歸：3 只有望大幅上漲的股票</li>
<li>3 只引領迷因股票復興的股票</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Kiniksa Pharmaceuticals International 嗎？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nebula Research & Development LLC 持有 Kiniksa Pharmaceuticals International, plc 價值 193 萬美元的股份